Insmed Inc

NASDAQ: INSM
$73.75
+$1.08 (+1.5%)
Real Time Data Delayed 15 Min.

INSM Stock Chart and Intraday Price

INSM Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 700 US HIGHWAY 202/206, BRIDGEWATER, NJ, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 4,166.69M USD
Shares Outstanding 148,492,000
Insmed Inc is a biopharmaceutical firm focused on developing and marketing treatments for patients with serious and rare diseases globally. Its flagship product, ARIKAYCE, targets Mycobacterium avium complex lung disease in adults. The company is also working on Brensocatib for bronchiectasis and other diseases, and Treprostinil Palmitil Inhalation Powder for certain types of pulmonary hypertension. Founded in 1988, Insmed is based in Bridgewater, New Jersey, serving patients in the US, Europe, Japan, and beyond.

INSM Articles

Thursday's top analyst upgrades and downgrades included Alphabet, Eli Lilly, Etsy, Microsoft, Mosaic, NetApp, Omega Healthcare Investors, RTX, Sherwin-Williams, Spotify Technology, Walt Disney and WW...
Thursday's top analyst upgrades and downgrades included Airbnb, Applied Materials, AutoZone, BorgWarner, Carvana, Dominion Energy, EQT, MongoDB, NRG Energy, PagSeguro Digital, Southwestern Energy,...
Wednesday's top analyst upgrades and downgrades included Albemarle, Camping World, eBay, EOG Resources, Etsy, Global Payments, IMAX, JPMorgan Chase, MetLife, Otis Worldwide, Salesforce, Wayfair and...
Thursday's top analyst upgrades and downgrades included Alphabet, Allstate, Antero Midstream, Archer Daniels Midland, Capital One Financial, Chipotle Mexican Grill, Corning, Microsoft, PepsiCo,...
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic selling...